AstraZeneca PLC Logo

AstraZeneca PLC

Global biopharma developing medicines for oncology, cardiovascular, respiratory & rare diseases.

AZN | IL

Overview

Corporate Details

ISIN(s):
GB0009895292 (+925 more)
LEI:
PY6ZZQWO2IZFZC3IOL08
Country:
United Kingdom
Address:
1 FRANCIS CRICK AVENUE, CB2 0AA CAMBRIDGE
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

AstraZeneca PLC is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. The company's primary therapeutic areas include Oncology, Cardiovascular, Renal & Metabolism, Respiratory & Immunology, and Rare Diseases. AstraZeneca develops, manufactures, and sells pharmaceutical and biotechnology products aimed at addressing complex health challenges for millions of patients worldwide. The firm maintains a significant research and development pipeline to create innovative treatments and transform healthcare through scientific advancement.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-12-01 16:15
Share Issue/Capital Change
Block listing Interim Review
English 14.9 KB
2025-12-01 16:10
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
English 8.8 KB
2025-11-26 08:25
Regulatory Filings
Imfinzi approved in US for early gastric cancer
English 33.0 KB
2025-11-24 08:25
Regulatory Filings
AstraZeneca manufacturing investment in Maryland
English 11.5 KB
2025-11-20 08:25
Regulatory Filings
Koselugo (selumetinib) approved in the US
English 22.0 KB
2025-11-17 16:10
Major Shareholding Notification
Holding(s) in Company
English 24.7 KB
2025-11-14 12:10
Director's Dealing
Director/PDMR Shareholding
English 21.7 KB
2025-11-10 16:10
Director's Dealing
Director/PDMR Shareholding
English 18.9 KB
2025-11-06 08:20
Earnings Release
9M and Q3 2025 results
English 865.0 KB
2025-11-06 08:00
Earnings Release
English 1.4 MB
2025-11-03 17:10
AGM Information
Result of General Meeting
English 16.9 KB
2025-11-03 17:06
AGM Information
Special Resolution Approved at General Meeting
English 78.4 KB
2025-11-03 16:59
Registration Form
Articles of Association approved at General Meeting
English 569.8 KB
2025-11-03 16:10
Declaration of Voting Results & Voting Rights Announcements
Total Voting Rights
English 8.8 KB
2025-10-28 08:05
Board/Management Information
Director Declaration
English 7.4 KB

Automate Your Workflow. Get a real-time feed of all AstraZeneca PLC filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for AstraZeneca PLC

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for AstraZeneca PLC via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-11-13 Philip Broadley Other Buy 980 99,665.12 EUR
2024-03-08 Pascal Soriot Other Other 105,238 N/A
2024-03-05 Pascal Soriot Other Other 17,702 N/A
2024-03-04 Pascal Soriot Other Other 109,872 11,076,196.32 EUR
2024-03-04 Aradhana Sarin Other Other 59,125 5,960,391.25 EUR
2023-12-12 Anna Manz Other Buy 487 49,623.16 EUR
2023-11-22 Michel Demare Other Buy 1,000 101,700.00 EUR
2023-11-21 Michel Demare Other Buy 1,000 101,052.24 EUR
2023-04-28 Michel Demare Other Buy 2,000 234,020.00 EUR
2023-03-23 Pascal Soriot Other Other 138,093 N/A

Peer Companies

MYUNGMOON PHARM CO.,LTD Logo
Develops, manufactures, and commercializes prescription & OTC medicines for global markets.
South Korea
017180
Nanexa AB Logo
Develops long-acting injectables using its proprietary nanotechnology for its own pipeline and partners.
Sweden
NANEXA
Nanobiotix Logo
Develops a first-in-class radioenhancer to amplify radiotherapy's effect directly within tumors.
France
NANO
Nanobiotix S.A. Logo
Developing a nanotherapeutic radioenhancer that amplifies radiation to destroy solid tumors.
United States of America
NBTX
Nanoform Finland OYJ Logo
Pharma tech firm engineering nanoparticles to enhance drug performance and development.
Finland
NANOFH
NanoRepro AG Logo
Develops and distributes rapid diagnostic self-tests for early disease detection.
Germany
NN6
Nasus Pharma Ltd Logo
Develops powder-based intranasal drugs for rapid delivery in acute medical emergencies.
United States of America
NSRX
NATURAL ALTERNATIVES INTERNATIONAL INC Logo
A science-based formulator and contract manufacturer of private-label nutritional supplements.
United States of America
NAII
Biotech R&D of natural ingredients for health and wellness solutions.
South Korea
168330

Talk to a Data Expert

Have a question? We'll get back to you promptly.